Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized anti-tuberculosis regimens for drug-susceptible pulmonary tuberculosis with diabetes mellitus
ChiCTR2100044663Phase 3Recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isoniazid, rifampicin, pyrazinamide and ethambutol in pulmonary tuberculosis (TB) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Recurrence rate within 2 years after successful treatment. Started Apr 2021; status: recruiting.
02
Drugs
isoniazidrifampicinpyrazinamideethambutol
03
Conditions
pulmonary tuberculosis (TB)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2100044663.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044663.